Introduction: This randomized clinical study compared the in vivo antibacterial efficacy of Reciproc Blue (RB), XP-endo Shaper (XP-S),XP-endo Shaper associated with XP-endo Finisher (XP-F) systems in infected oval-shaped root canals with primary apical periodontitis.Methods: In this study, 28 human teeth with a single root and a single canal were randomly assigned to two groups according to the instrumentation technique: group-1, RB (n = 14) and group-2, XP-endo (XP-S and XP-F, n = 14). The single-rooted teeth were prepared by reciprocating and rotary nickel-titanium (NiTi) instruments with 5.25% sodium hypochlorite irrigation. Samples were collected from the canal at the baseline (S1), after chemomechanical preparation (S2), and after XP-F instrumentation (S3). The DNA extracts were subjected to quantitative analysis for total bacterial counts by quantitative real-time polymerase chain reaction. The data were analyzed using the analysis of variance test (ANOVA), and the level of significance was set at 5%.
Results:All samples tested positive for the presence of bacteria at baseline, and the bacterial counts substantially reduced after treatment procedures (P < 0.01). The results showed no statistical difference between RB and XP-S instrumentation with respect to the bacterial reduction (P ˃ 0.05). A marked bacterial reduction was observed after the use of the XP-F instrument (P < 0.01).
Conclusion:The XP-S and RB systems sharply reduced the bacterial load in oval-shaped root canals with primary apical periodontitis. XP-F, used as a supplementary instrument to chemomechanical preparation, promoted a significantly higher bacterial reduction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.